Enhancing BCMA CAR t-cell efficacy through glutamine transporter ASCT2 overexpression
A novel approach to improve BCMA CAR T-cell therapy by engineering cells to overexpress the glutamine transporter ASCT2, enhancing their metabolic fitness and antitumor efficacy in glutamine-deprived environments common ...